Abstract
Among the problems related to the treatment of classic hemophilia, the presence of inhibitors (alloantibodies) to foreign Factor VIII (F.VIII) is one of the most serious. These antibodies may arise at any age, but the cumulative risk of developing an inhibitor one year after the first treatment with a factor concentrate is between 22% and 25%. 1,2The presence of such antibodies can render any further administration of F.VIII ineffective. On the basis of the speed and degree of immune response to F.VIII, patients have been divided into high- and low-responders.3This is an arbitrary classification, but it is related to important treatment characteristics. Low responders, that is patients whose maximum inhibitor titer is <10 Bethesda Units (B.U.), can be treated with F.VIII, albeit at higher doses; however, high-responders can seldom be treated with F.VIII and comprise the so-called “refractory hemophiliacs.”
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
S. Ehrenforth, W. Kreuz, I. Sharrer, R. Linde, M. Funk, T. Gungor, B. Krackhardt, and B. Kornhuber, Incidence of development of factor VIII and factor IX inhibitors in hemophiliacs, Lancet 339:594 (1992).
J.M. Lusher, S. Arkin, C.F. Abilgaard, R.S. Schwartz and the Kogenate Previously Untreated Patient Study Group, Recombinant Factor VIII for the treatment of previously untreated patients with hemophilia A, N. Engl. J. Med. 328:453 (1993).
J. P. Allain, D. Frommel, Antibodies to factor VIII. V. Patterns of immuneresponse to factor VIII in hemophilia A, Blood 47:973 (1976).
H. H. Brackmann, J. Gormsen, Massive factor-Vlriinfusion in hemophiliac with factor VIII inhibitor, high responder, Lancet 2:933 (1977).
H.H. Brackmann, Induced immune tolerance in factor VIII inhibitor patients, Progr Clin Biol Res 150:181 (1984).
G.C. White, R.E. Taylor, P.M. Blatt, H.R. Roberts, Treatment of a high-titre anti-factor VIII antibody for continuous factor VIII administration:Report of a case, Blood 62:141 (1983).
J.A. Aznar, J.J. Jorquera, A. Peiro, I. Garcia, The importance of corticoids added to continuous treatment with factor VIII concentrates in the suppression of inhibitors in haemophilia A, Thromb Haemost 51:217 (1984).
S. Stenbjerg, J. Ingerslev, E. Zacharie, Factor VIII inhibitor treatment with high doses of FVIII, Thromb Res 34:533 (1984).
E. Scheibel, C. Feddersen, H. Hertz, Long-term high dose factor VIII treatment of 3 hemophiliacs with factor VIII inhibitor, Scand J Haematol 34:378 (1985).
E. F. van Leewen, E.P. Mauser-Bunschoten, RJ. van Dijken, A. J. Kok, E.J.M. Sjamsedin-Visset, J.J. Sixma, Disappearance of factor VIILC antibodies in patients with hemophilia A upon frequent administration of factor VIII in intermediate or low dose, Br J Haematol 64:291 (1986).
U.E. Scheibel, J. Ingerslev, J. Dalsgaard-Nielsen, S. Stenbjerg, J. B. Knudsen and the Danish Study Group, Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state:A description of eleven patients treated, Thromb Haemost 58:1049 (1987).
N. Ewing, N.L. Sanders, S. L. Dietrich, C. K. Kasper, Induction of immune tolerance to Factor VIII in hemophiliacs, JAMA 259:65 (1988).
R.A. Gruppo, Immunetolerance induction with once weekly factor VIH infusions in patients with hemophilia A and inhibitors, Thromb Haemost 65:1168 (1991) (abstract).
G. Mariani, S. Solinas, D. Pasqualetti, A. Ghirardini, P. Verani, S. Butto, M. Lopez, T. Moretti, Induction of Immunetolerance in hemophilia for high titre inhibitor eradication:A long term follow-up, Thromb Haemost 62:835 (1989).
C.K. Kasper, LM. Aledort, R.B. Counts, J.R. Edson, J. Fratantoni, D. Green, J.W. Hampton, M. W. Hilgartner, J. Lazeson, P.H. Levine, C.W. McMillan, J. Pool, S.S. Shapiro, N.R. Shulman, J. Van Eye, A more uniform measurement of factor VIII inhibitors, Thromb Diath Haemorrh 34:875 (1975).
A.G. Dean, J.A. Dean, A.H. Burton, R.C. Dicker, Epi Info, version 5:A word processing, database and statistics program for epidemiology on microcomputers. USD Inc., Stone Mountain, GA, 1990.
W.J. Dixon, 1985, “BMPD statistical software,” University of California Press, Berkeley, CA.
J.L. Fleiss, 1973, “Statistical methods for rates and proportions,” John Wiley & Sons, Inc., New York, NY.
I.M. Nilsson, E. Berntorp, O. Zettervall, Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII, N Engl J Med 318:947 (1988).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Plenum Press, New York
About this chapter
Cite this chapter
Mariani, G. et al. (1995). Immune tolerance to Factor VIII:The international registry data. In: Aledort, L.M., Hoyer, L.W., Lusher, J.M., Reisner, H.M., White, G.C. (eds) Inhibitors to Coagulation Factors. Advances in Experimental Medicine and Biology, vol 386. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0331-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0331-2_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8001-6
Online ISBN: 978-1-4613-0331-2
eBook Packages: Springer Book Archive